Drug Discovery Quiz Answer. In this post you will get Quiz Answer Of Drug Discovery
Drug Discovery Quiz
Offered By ”University of California San Diego”
Week- 1
Pharma and Biotech
1.
Question 1
According to the videos, in what direction is the pharmaceutical and biotechnology industry headed?
1 point
- Efficiency.
- Innovation and cost reduction.
- Better and more powerful drugs.
- Equity and Equality.
2.
Question 2
In terms of pharmaceutical developments, why has there been a shift to countries such as Asia?
1 point
- A desire for a larger market.
- A desire for increased STEM (Science, Technology, Engineering, and Mathematics).
- A desire for cost reduction.
- A desire for more employment.
3.
Question 3
Please observe the following graph:
As mentioned in the lectures, what is the main cause of the apparent rise in financial penalties in the U.S.?
1 point
- Strengthening scientific base.
- Tight regulations.
- Patent Cliffs.
- Escalating demands for medicine.
4.
Question 4
Which of the following are opportunities for the pharma market? (Choose 3)
1 point
- Wireless Health.
- Healthcare reduction costs.
- Trade liberalization.
- Strengthening Scientific base.
- Stronger Price controls.
5.
Question 5
According to the videos, who or what determines Pharma and Biotech innovation?
1 point
- The cost of the drug
- The investors
- The customers
- The advancement of the field
6.
Question 6
According to the videos, what is the ultimate future or direction of the Pharma company?
1 point
- Ultimate personalized medicine.
- Biomarkers.
- Diversity of drugs.
- Repurposing of drugs.
7.
Question 7
What type of product distribution model leads to siloed markets?
1 point
- Specialist model
- Business model
- Customer centered model
- Blockbuster model
8.
Question 8
What are the characteristics of the blockbuster model? (Choose 2)
1 point
- Pricing – Depends on the market
- Pricing – Pay for performance
- R&D – Nimble decision-making process
- R&D – Silos
9.
Question 9
According to the videos, what is disruptive innovation in pharma?
1 point
- Cure a disease or prevent it.
- Improve the quality of life.
- Superiority in comparative trials.
- Reduce the cost of care.
10.
Question 10
Payers are not going to pay a premium unless… (Choose 2)
1 point
- Drug shows disruptive innovation.
- Pharma race to develop new products, which all have the same mode of action.
- Reduce the cost of care.
- Be better than other drugs in trials and be cost efficient.
- Improve the quality of life.
11.
Question 11
What makes specialty drugs less costly to develop compared to most prevalent diseases?
1 point
- Expedited reviews by the FDA and tax breaks
- Clinical trials are smaller, only 100-200 subjects compared to several thousand
- Seven years of competition-free marketing for new orphan drugs
- Lower standard for scientific evidence required for orphan drugs
Week- 2
Drug Discovery: Proteomics, Genomics
1.
Question 1
What is the current referred issue of the omnics era when Dr.Philip used the analogy about neglecting the “long tail”?
1 point
Increased R&D spending but decrease in new drug approvals.
Funders are demanding data sharing plans.
DNA data is doubling every 5 months.
No one is taking care of errors, complexity, etc of the massive genome data.
2.
Question 2
Data we obtain from analyzing organisms are not only getting ___ but also getting ____.
1 point
Larger; More complex.
Complex; More unstructured.
3.
Question 3
Metagenomics is the study of genetic material recovered directly from environmental samples. What was one of the biggest challenges with metagenomics as mentioned in lecture?
1 point
Almost all data captured is completely new and rich with data.
Open sourcing data published.
We had to study human microbiomes.
Establishing a data science major.
4.
Question 4
What is open source publishing?
1 point
Giving out the source code of the code for the general public.
Making information accessible to everyone.
Acknowledgement of the author in a particular work.
5.
Question 5
What is the warning or problem with the massive amount of data growth and complexity?
1 point
The data is too complex to analyze.
Lack of proper genome sequencing methods.
Not enough data scientists.
30% of annotations in databases may be wrong.
6.
Question 6
What is our current mentality in the drug discovery process that is impeding the process?
1 point
One drug, multiple targets, multiple diseases.
Heal as many people as possible.
Maximize profit.
One drug, one target, one disease.
7.
Question 7
Why is the single silver bullet mentality bad for the drug development process?
1 point
Too risky for the company to invest in only one market.
Increases the time required to develop the drug.
Compounds often bind to more than one target.
8.
Question 8
How could computers aid in the unique processes of network pharmacology?
1 point
Calculate and aid in analysis of physiological processes.
Store massive protein data as databases to be analyzed later.
Computers cannot aid the process of network pharmacology because it cannot be as accurate as humans.
Simulate and analyze biological networks.
9.
Question 9
What is the major caution with working with systems pharmacology and computers?
1 point
Computers are too slow to deal with complexity.
There is a general mistrust with computational approaches.
Openness is an alien culture to drug discovery.
10.
Question 10
Which of the following is a major limitation of metagenomics?
1 point
Functional annotation accuracy
Scientific interest
Information technology (IT) infrastructure
Lack of data regarding function
11.
Question 11
Off-target drug screening provides information on all of the following EXCEPT:
1 point
Reason a drug failed
How to optimize a new chemical entity
Drug dose and frequency
A possible repositioning of a drug to treat a different disease
12.
Question 12
Multiscale modeling of drug actions include all of the following EXCEPT:
1 point
Understanding of dynamics and kinetics of protein-ligand interactions
Knowledge representation and discovery and model integration
Systems pharmacology
Reconstruction, analysis and simulation of biological networks
Compound Selection and Pre-clinical Studies
1.
Question 1
What is the success rate from research to market?
1 point
1 in 1000
1 in 10
1 in 100
2.
Question 2
Why are pharmaceutical companies placing focus (such as improvements and cost reduction) on the research and development branch?
1 point
R&D is too competitive and over inflated with non-productive workers.
Better R&D means better drugs which means improved sells.
R&D always requires large attention.
R&D takes the longest and has the highest investment in the drug development cycle.
3.
Question 3
Which is the best definition of the term First-In-Class?
1 point
The first product on shelves that customer will naturally get.
The first molecule designed to tackle a new problem.
A monopoly on a specific medical brand.
4.
Question 4
The videos mentioned a desire for robust efficacy in animal models for R&D requirements. What does it mean to have robust efficacy in animal models?
1 point
Have reproducible effect in a dose response manner: small dose => small repose, large dose=> large response.
Show a problem is able to be addressed by a specific variable threshold.
Joint ownership and responsibility of the animal tests.
5.
Question 5
When a medicine is designed for oral intake use, would the testing process test the medicine in non-oral intake ways?
1 point
Yes
No
6.
Question 6
What is the Ames Assay?
1 point
Another name for tier 3 of the research testing.
A type of report required for the composition of the chemical compound.
A type of test within the assay flow to detect the genetic toxicity of the compound.
7.
Question 7
Which is the best description of what X-Ray crystallography does?
1 point
Determines the genetic toxicity of a compound.
Determines the half life of the compound.
Finds the structure of the compound.
8.
Question 8
Of the following questions, which best represents the problem that Pharmacokinetic is trying to tackle?
1 point
What is going on in the body when the compound enters into it?
How does the oxidative process work on the compound?
How will your drug interact with other drugs on the market?
How does the drug affect the DNA?
9.
Question 9
Which of the following statements is true? (Select 2)
1 point
Small molecule drug candidates should activate both hERG and CYP450 proteins
One of the FDA requirements for small molecule drug candidates is to not inhibit hERG channel.
Small molecule drug candidates should not inhibit the cytochrome CYP450
10.
Question 10
What is SPR (surface plasmon resonance)?
1 point
A method to measure the change in fluorescence of a protein upon a small molecule binding,
A method to measure the effect of temperature on protein stability.
A label-free method which is used to characterize the kinetics of protein-ligand interactions. It provides the values for Kd, Ka, stoichiometry and kon/koff parameters.
11.
Question 11
Which of the following is considered a third tier study?
1 point
Receptor binding study
Ames mutagenicity study
Dose escalation pharmacokinetic study
Animal model protein binding study
12.
Question 12
Which of the following is an inappropriate criteria for drug discovery?
1 point
Unknown efficacy in rodent automimmune disease models
Suitable for oral, once daily dosing
Target selectivity
Structurally unique molecule
13.
Question 13
All of the following are common in vivo models for pharmacokinetic/pharmacodynamic profiling EXCEPT:
1 point
Cynomolgus monkeys
Sprague-Dawley rats
Beagle dogs
Bobtail Cats
14.
Question 14
Which of the following are typical compound criteria in research?
1 point
Structurally unique molecule
Target selectivity >1,000 fold selective vs. closely related target
Focus on First-in-Class or Best-in-Class
Efficacy in relevant animal models
15.
Question 15
Which of the following is used as an antitarget to evaluate potential cardiotoxicity?
1 point
hERG
HepG2 cytotoxicity panel
Ames mutagenicity test
Human 5 major P450s
16.
Question 16
Which of the following parameters are typical in pharmakokinetics and pharmakodynamics?
1 point
Half-life in blood
Interaction with other drugs
Induction of cytochrome P450s
Inhibition of cytochrome P450s
17.
Question 17
Which of the following preclinical tests and animal methods were used in testing a compound for treatment of diabetes?
1 point
Different mouse strains
Non-Obese/Diabetic rats
Immunehistochemical staining of insuline in microscopic sections of Langerhans’ islets in the pancreas
Monkeys
Week- 3
Challenges in Fragment Based Drug Discovery for Protein Kinases
1.
Question 1
All of the following are suitable target directed screening methods EXCEPT:
1 point
2.
Question 2
All of the following are perceived or real challenges to fragment-based drug discovery EXCEPT:
1 point
3.
Question 3
All of the following are suitable for an oral drug candidate EXCEPT:
1 point
4.
Question 4
cLogP is a measure of compound lipophilicity. What compound property does P represent?
1 point
5.
Question 5
Which of the following is the right value for a compound to be suitable drug candidate?
1 point
6.
Question 6
The equation
LLE =-log(IC50) – cLogP
describes the relationship between the value of Lipophilic Ligand Efficiency (LLE) and some compound properties.
What does IC50 represent?
1 point
7.
Question 7
All of the following are correct statements EXCEPT which one?
1 point
8.
Question 8
Compound efficacy contributes for about 1/3 of the failed cases in small molecule drug discovery. Which of the following statements defines the meaning of Efficacy?
1 point
9.
Question 9
All EXCEPT one are correct statements. Please identify the wrong statement.
Medicinal chemists are facing the following challenges when they synthesise compounds that are candidates for drug discovery:
1 point
10.
Question 10
What is the main goal of the Fragment Based Drug Discovery approach?
1 point
Concepts in Drug Delivery Quiz
1.
Question 1
Which of the following poses a challenge to the oral absorption of drugs?
1 point
2.
Question 2
Which of the following is a physiologic factor that influences the oral absorption of a drug?
1 point
3.
Question 3
Which of the following is a disadvantage of nasel systemic delivery?
1 point
4.
Question 4
ADME refers to what?
1 point
5.
Question 5
What is “kinetics” referring to in “pharmacokinetics”?
1 point
6.
Question 6
Which three of the following are challenges to oral absorption? (select 3)
1 point
